Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ENILCONAZOLE CRS (60 MG)

ENILCONAZOLE CRS (60 MG)

35554-44-0

DISCOVER
ENILCONAZOLE IMPURITY E CRS (20 MG)

ENILCONAZOLE IMPURITY E CRS (20 MG)

24155-42-8

DISCOVER
FLUBENDAZOLE CRS (25 MG)

FLUBENDAZOLE CRS (25 MG)

31430-15-6

DISCOVER
FLUBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

FLUBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

31430-15-6

DISCOVER
IBUPROFEN IMPURITY F CRS (5 MG)

IBUPROFEN IMPURITY F CRS (5 MG)

NA

DISCOVER
IOXAGLIC ACID CRS (125 MG)

IOXAGLIC ACID CRS (125 MG)

59017-64-0

DISCOVER
IOXAGLIC ACID IMPURITY A CRS (20 MG)

IOXAGLIC ACID IMPURITY A CRS (20 MG)

22871-58-5

DISCOVER
MALIC ACID - REFERENCE SPECTRUM (N/A)

MALIC ACID - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
MEBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

MEBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

31431-39-7

DISCOVER
METOPROLOL IMPURITY A CRS (15MG)

METOPROLOL IMPURITY A CRS (15MG)

NA

DISCOVER
NADOLOL CRS (100 MG)

NADOLOL CRS (100 MG)

42200-33-9

DISCOVER
PHENYLBUTAZONE IMPURITY B CRS(20 MG)

PHENYLBUTAZONE IMPURITY B CRS(20 MG)

NA

DISCOVER